Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110314 | 0.88 | ALDH1A1 (0.32) | ALDH1A1MAPTP2RX7NTRK1 | |
| SCHEMBL17110315 | 0.86 | ALDH1A1 (0.32) | ALDH1A1MAPTKMT2ANTRK1 | |
| SCHEMBL17098813 | 0.84 | VCAM1 (0.37) | ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL17098811 | 0.84 | VCAM1 (0.37) | ALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL17110302 | 0.84 | ALDH1A1 (0.33) | ALDH1A1MAPTNTRK1 | |
| SCHEMBL17110287 | 0.83 | — | — | |
| SCHEMBL17110316 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPTSMN1; SMN2KMT2AP2RX7 | |
| SCHEMBL17110290 | 0.82 | — | — | |
| SCHEMBL17110299 | 0.82 | LPAR1 (0.34) | ALDH1A1MAPTKMT2ANTRK1 | |
| SCHEMBL17110284 | 0.80 | ALDH1A1 (0.30) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | ALDH1A1 923/4885MAPT 3584/4885RAB9A 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.